The "la Caixa" Foundation supports three biomedical innovation projects to help them move from the laboratory to the market and society
The "la Caixa" Foundation has awarded three new grants to cutting-edge biomedical innovation projects within the framework of the CaixaResearch Consolidate call. The ultimate aim of CaixaResearch Consolidate is to support mature projects such as those selected so that they can take the step from the laboratory to the market and society, creating new companies or solutions based on research and thus improving people's health and quality of life.
This year's winners are a project from the Universitat Rovira i Virgili (URV) in consortium with researchers from the Institut d'Investigació Sanitària Pere Virgili (IISPV), to create new medical devices that improve the monitoring of electrical brain signals in neonates and adults; one from the Fundació Bosch i Gimpera, University of Barcelona, in consortium with researchers from the University of Granada and the University of Catania to develop new drugs to reduce pain, and one from the Germans Trias i Pujol Research Institute (IGTP) to develop a new immunotherapy based on a monoclonal antibody for the treatment of cancer.
These projects will receive financial support of 300,000 euros each for their development over the next two years. The aid will go to areas such as the technological development of the asset, studies for regulatory approval, recruitment of personnel and management of intellectual property, among others.
In addition, their researchers will receive personalised mentoring support and other support activities such as expert advice in defining their development and commercialisation plans.
Since 2015, the "la Caixa" Foundation has allocated 18 million euros to 173 innovative projects between the CaixaResearch Validate, for innovations in earlier stages, and CaixaResearch Consolidate calls. The projects have generated an additional investment of more than 10 million euros and 29 spin-off companies have been created.
